SteelPeak Wealth LLC Purchases 1,005 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

SteelPeak Wealth LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 40.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,480 shares of the biopharmaceutical company's stock after acquiring an additional 1,005 shares during the quarter. SteelPeak Wealth LLC's holdings in Alnylam Pharmaceuticals were worth $819,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Huntington National Bank boosted its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $42,000. True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $45,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ ALNY traded up $3.17 during mid-day trading on Thursday, reaching $277.16. 561,204 shares of the company traded hands, compared to its average volume of 690,037. The company's fifty day moving average is $249.42 and its two-hundred day moving average is $260.65. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a market cap of $35.75 billion, a PE ratio of -105.79 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the previous year, the firm earned $1.15 EPS. The company's revenue was down 33.3% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a research note on Monday, October 14th. TD Cowen upped their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 1st. Piper Sandler reissued an "overweight" rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, HC Wainwright restated a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $298.61.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 1,682 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock worth $20,622,925 over the last three months. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.